Cover Image

Immunogenicity assessment of elder hepatocellular carcinoma patients after inactivated whole-virion SARS-CoV-2 vaccination

Background Research on immunogenicity after 3rd SARS-CoV-2 vaccine in elder hepatocellular carcinoma (HCC) was limited. This study aimed to investigate the efficacy and influencing factors of inactivated SARS-CoV-2 vaccine in elder HCC. Research design and methods We assessed total antibodies, anti-...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ruyun Gao (Author), Cuiling Zheng (Author), Mengwei Yang (Author), Liyuan Dai (Author), Chen Chen (Author), Jiarui Yao (Author), Zhishang Zhang (Author), Le Tang (Author), Yuankai Shi (Author), Xiaohong Han (Author)
Format:	Book
Published:	Taylor & Francis Group, 2023-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine
by: Cecilia Montalban, et al.
Published: (2018)

Immunogenicity and safety of inactivated Influenza Split-Virion vaccine administered via a Transdermal Microneedle System
by: Mahmoud Ameri, et al.
Published: (2021)

How to Increase the Immunogenicity of SARS-COV-2 Inactivated Vaccines?
by: Yousef Khadivi
Published: (2021)

Immunogenicity and safety of an intramuscular split-virion quadrivalent inactivated influenza vaccine in individuals aged ≥ 6 months in India
by: Sharad Agarkhedkar, et al.
Published: (2019)

Immunogenicity of Inactivated SARS-CoV-2 Vaccines in Patients With Rheumatoid Arthritis: A Case Series
by: Ting Zhao, et al.
Published: (2022)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial
by: Yongliang Feng, et al.
Published: (2021)

Immunogenicity and safety of the quadrivalent inactivated split-virion influenza vaccine in populations aged ≥ 3 years: A phase 3, randomized, double-blind, non-inferiority clinical trial
by: Jianmin Chen, et al.
Published: (2023)

CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2
by: Lairun Jin, et al.
Published: (2022)

Evaluation of immunogenicity post two doses of inactivated SARS-CoV-2 vaccine, Covaxin after six months
by: Rima R. Sahay, et al.
Published: (2022)

Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers
by: Ahmet Soysal, et al.
Published: (2021)

A phase 2/3 double-blind, randomized, placebo-controlled study to evaluate the safety and immunogenicity of a seasonal trivalent inactivated split-virion influenza vaccine (IVACFLU-S) in healthy adults in Vietnam
by: Phan Trong Lan, et al.
Published: (2019)

Safety and immunogenicity of a quadrivalent, inactivated, split-virion influenza vaccine (IIV4-W) in healthy people aged 3-60 years: a phase III randomized clinical noninferiority trial
by: Xiaoyuan Huang, et al.
Published: (2022)

Safety and immunogenicity of the third (booster) dose of inactivated and recombinant protein SARS-CoV-2 vaccine for patients with endocrine-related cancer
by: Shanshan Han, et al.
Published: (2023)

Preliminary results on novel adjuvant combinations suggest enhanced immunogenicity of whole inactivated pandemic influenza vaccines
by: Allegra Peletta, et al.
Published: (2024)

Immunogenicity and protective efficacy of an inactivated SFTS vaccine candidate in mice
by: Aqian Li, et al.
Published: (2022)

Immunogenicity of inactivated COVID-19 vaccines at different vaccination intervals
by: Juan Li, et al.
Published: (2021)

Hesitancy, reactogenicity and immunogenicity of the mRNA and whole-virus inactivated Covid-19 vaccines in pediatric neuromuscular diseases
by: Michael Kwan Leung Yu, et al.
Published: (2023)

Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18-60 years of age in the Republic of Korea
by: Won Suk Choi, et al.
Published: (2018)

Enhanced passive safety surveillance of a quadrivalent inactivated split virion influenza vaccine in Finland during the influenza season 2020/21
by: Olga Syrkina, et al.
Published: (2022)

Whole inactivated dengue virus-loaded trimethyl chitosan nanoparticle-based vaccine: immunogenic properties in ex vivo and in vivo models
by: Tuksin Jearanaiwitayakul, et al.
Published: (2021)

COVID-19: The biology behind the virion
by: V Vasanthi, et al.
Published: (2020)

Immunogenicity of inactivated rotavirus in rhesus monkey, and assessment of immunologic mechanisms
by: Yan Zhou, et al.
Published: (2023)

VITT with inactivated SARS-CoV-2 vaccine - index case
by: Kanta Devi, et al.
Published: (2022)

Immunogenicity and safety of a trivalent inactivated influenza vaccine
by: Eddy Fadlyana, et al.
Published: (2011)

Enhanced passive safety surveillance of the quadrivalent inactivated split-virion influenza vaccine (IIV4) in Finland during the 2019/20 influenza season
by: Anne-Laure Chabanon, et al.
Published: (2021)

Inactivation and Recovery of High Quality RNA From Positive SARS-CoV-2 Rapid Antigen Tests Suitable for Whole Virus Genome Sequencing
by: Guerrino Macori, et al.
Published: (2022)

Early Humoral Responses of Hemodialysis Patients After Inactivated SARS-CoV-2 Vaccination
by: Zhao WM, et al.
Published: (2022)

Lot-to-lot consistency, immunogenicity, and safety of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults: A randomized, double-blind, phase IV trial
by: Dandan Zhu, et al.
Published: (2022)

Safety and immunogenicity of the first Kazakh inactivated vaccine for COVID-19
by: Ainur Nurpeisova, et al.
Published: (2022)

EVALUATION OF REACTOGENICITY, SAFETY AND IMMUNOGENICITY OF INACTIVATED MONOVALENT VACCINE IN CHILDREN
by: A.N. Mironov, et al.
Published: (2010)

EVALUATION OF REACTOGENICITY, SAFETY AND IMMUNOGENICITY OF INACTIVATED MONOVALENT VACCINE IN CHILDREN
by: A.N. Mironov, et al.
Published: (2010)

Willingness-to-pay for a booster dose of inactivated SARS-CoV-2 vaccine in Taizhou, China
by: Tao-Hsin Tung, et al.
Published: (2022)

La representación gráfica del virión del SARS-CoV-2 en España: comparación entre la prensa impresa y los informativos televisivos
by: Gema Bonales Daimiel, et al.
Published: (2020)

Construction of the Enterococcal Strain Expressing Immunogenic Fragment of SARS-Cov-2 Virus
by: Alexander Suvorov, et al.
Published: (2022)

An Algae-Made RBD from SARS-CoV-2 Is Immunogenic in Mice
by: Dania O. Govea-Alonso, et al.
Published: (2022)

Hypochlorous acid inactivates oral pathogens and a SARS-CoV-2-surrogate
by: Kento Tazawa, et al.
Published: (2023)

Neutralizing Antibody Response by Inactivated SARS-CoV-2 Vaccine on Healthcare Workers
by: Nataniel Tandirogang, et al.
Published: (2023)

Immune response and safety of inactivated SARS-CoV-2 vaccines during pregnancy: a real-world observational study
by: Yajie Gong, et al.
Published: (2023)

Preclinical evaluation of the immunogenicity and safety of an inactivated enterovirus 71 candidate vaccine.
by: Shi-Hsia Hwa, et al.
Published: (2013)

Safety and immunogenicity of inactivated COVID-19 vaccination in adult rheumatic patients in South China: a prospective study
by: Huiqiong Zeng, et al.
Published: (2022)